Adicet Bio

ACET · NASDAQ

$4.52−$0.01 (−0.22%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $4.53

ACET analyst rating

BuyConsensus of 5 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy5
Hold0
Underperform0
Sell0

12-month price target · 8 analysts

Average $35.53 (+686.1% upside)

Low: $18.18
Now: $4.52
High: $94.50

Upgrades and downgrades

The latest rating actions, newest first

ACET analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wedbush	Sep 29, 2026	Maintains	Outperform	$25.00 → $28.00	39%
HC Wainwright & Co.	Sep 28, 2026	Maintains	Buy	$27.00 → $34.00	41%
HC Wainwright & Co.	Sep 18, 2026	Maintains	Buy	$27.00	41%
Guggenheim	Aug 6, 2026	Maintains	Buy	$100.00 → $90.00	49%
Jefferies	May 5, 2026	Initiates	Buy	$8.00 → $19.00	0%
HC Wainwright & Co.	Mar 23, 2026	Maintains	Buy	$50.00 → $27.00	41%
Guggenheim	Mar 13, 2026	Maintains	Buy	$128.00 → $100.00	49%
HC Wainwright & Co.	Jan 21, 2026	Maintains	Buy	$9.00 → $50.00	41%
Canaccord Genuity	Jan 6, 2026	Maintains	Buy	$128.00 → $18.00	35%
HC Wainwright & Co.	Nov 7, 2025	Maintains	Buy	$4.00 → $9.00	41%

The case for and against

Updated Oct 18, 2026

Bull case

Adicet Bio is viewed positively because prula-cel has shown compelling early clinical efficacy in heavily pretreated lupus nephritis and SLE, with 50% complete renal response at 12 months, 54% DORIS remission, and durable ongoing responses through 12 to 21 months. Its safety profile also stands out, with no CRS above Grade 2, no ICANS, no IEC-HS, and only 8.3% Grade 3 or higher infections, while all patients discontinued background immunosuppressants and most tapered steroids. The outlook is further supported by FDA-aligned pivotal study start-up next quarter, a planned double-digit enrollment trial, and the potential to expand into a roughly 70,000-patient U.S. non-renal SLE market, alongside near-term catalysts in 1H:27 and mid-2027.

Bear case

Adicet Bio is a clinical-stage biotechnology company facing substantial downside risk because its lead programs remain exposed to negative clinical data, safety signals, slower development, and regulatory failure. The outlook is further pressured by an inability to achieve sales estimates and by commercial competition from current and future therapies, which could prevent ADI-001 from proving efficacious or gaining meaningful traction. Even with a DCF framework using a 50% probability of approval, 11% discount rate, and 1.5% terminal growth rate, the projected $375M total market value implies material execution risk and potential medium- to long-term equity dilution.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.